M

D

MASSIMI , Davide

Last name: MASSIMI

First name: Davide

2021 (v1)

Publication

Metadata-only

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

Cingolani, Linda Barberio, Brigida Zingone, Fabiana

To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the ADA originator, after switching to them. We prospectively analyzed data collected from 55...

Uploaded on: February 14, 2024
2021 (v1)

Publication

Metadata-only

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

Barberio, Brigida Cingolani, Linda Canova, Cristina

Background: Adalimumab is an effective and safe biological drug for the treatment of inflammatory bowel disease (IBD). Nowadays, several biosimilar agents are available, but data regarding their efficacy and safety in patients with IBD are still lacking. We aimed to compare the effectiveness and tolerability between adalimumab originator,...

Uploaded on: January 13, 2024